Skip to main content
TipRanks
Go Ultimate75% OFF

BridgeBio Oncology Therapeutics (BBOT) Stock Price & Analysis

80 Followers

BBOT Stock Chart & Stats

$1.81-$0.05(-2.69%)
At close: 4:00 PM EST
$2.5$5$7.5Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$1.79 - $1.94
52-Week Range
$1.79 - $14.87
Previous Close
$1.86
Volume
N/A
Average Volume (3M)
632.75K
Market Cap
$149.27M
Enterprise Value
$137.27M
Total Cash (Recent Filing)
$193.87M
Total Debt (Recent Filing)
$2.38M
Price to Earnings (P/E)
―
Beta
0.84
Next Earnings
Mar 11, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Minimal Leverage

Minimal debt reduces interest burden and financial obligations while preserving flexibility to fund research internally. The conservative capital structure may help BBOT extend its operating runway and withstand funding pressure better than a highly leveraged biotechnology company.

Asset Base And Liquidity Runway

A sizable asset base relative to the company’s minimal debt provides a financial cushion while BBOT advances its oncology pipeline. This does not remove funding risk, but it can support continued research activity and reduce dependence on immediate borrowing.

Cash-Backed Losses

Losses that closely track negative free cash flow indicate that reported weakness is largely reflected in actual cash usage rather than being obscured by large non-cash charges. That transparency improves assessment of the business model and future funding needs.

Bears Say

No Revenue

The absence of revenue means BBOT has not yet demonstrated commercial product traction or an operating revenue base to fund research. Until sales begin, progress remains dependent on capital resources and successful development of oncology therapeutics.

Widening Losses

Losses have expanded materially over multiple reporting periods, showing that investment requirements are increasing faster than any demonstrated operating income. Persistent losses reduce financial flexibility and make future equity funding or asset use more consequential.

Accelerating Cash Burn

The sharp negative cash flow indicates that BBOT is consuming substantial cash to operate and develop its business. If this burn persists, the company may need to rely on its asset base or raise additional capital before reaching commercial self-sufficiency.

BridgeBio Oncology Therapeutics News

BBOT FAQ

What was BridgeBio Oncology Therapeutics’s price range in the past 12 months?
BridgeBio Oncology Therapeutics lowest stock price was $1.79 and its highest was $14.87 in the past 12 months.
What is BridgeBio Oncology Therapeutics’s market cap?
BridgeBio Oncology Therapeutics’s market cap is $149.27M.
When is BridgeBio Oncology Therapeutics’s upcoming earnings report date?
BridgeBio Oncology Therapeutics’s next earnings report is estimated for Mar 11, 2027 (not yet confirmed), which is in 109 days.
How were BridgeBio Oncology Therapeutics’s earnings last quarter?
BridgeBio Oncology Therapeutics released its earnings results on Nov 10, 2026. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.69 by $0.26.
Is BridgeBio Oncology Therapeutics overvalued?
According to Wall Street analysts BridgeBio Oncology Therapeutics’s price is currently Undervalued.
Does BridgeBio Oncology Therapeutics pay dividends?
BridgeBio Oncology Therapeutics does not currently pay dividends.
What is BridgeBio Oncology Therapeutics’s EPS estimate?
BridgeBio Oncology Therapeutics’s EPS estimate is -0.44.
How many shares outstanding does BridgeBio Oncology Therapeutics have?
BridgeBio Oncology Therapeutics has 80,251,270 shares outstanding.
What happened to BridgeBio Oncology Therapeutics’s price movement after its last earnings report?
BridgeBio Oncology Therapeutics reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.69. Following the earnings report the stock price went up 16.364%.
Which hedge fund is a major shareholder of BridgeBio Oncology Therapeutics?
Hedge funds hold BridgeBio Oncology Therapeutics shares: the largest hedge-fund position in BridgeBio Oncology Therapeutics is 72,324,570 shares, and hedge funds decreased their holdings by 289.5K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology